Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Metabolic Rate01:25

Metabolic Rate

The human body is a powerhouse of energy, with every cell performing numerous functions that require energy. This energy production and consumption is measured by the metabolic rate, which quantifies the total heat generated by all the body's chemical reactions and mechanical work. This measurement helps to determine the rate of kilocalorie (kcal) consumption needed to fuel all ongoing activities.
The Basal Metabolic Rate (BMR) measures the energy expended at rest.
Several factors influence the...
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

'Jinju' Pomelo pollen enhances fruit set and development in Citrus maxima 'Tomentosa': physiological and proteomic associations.

BMC plant biology·2026
Same author

[Effect of glycemic variability on the efficacy of artificial pancreas systems: A real-world study].

Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences·2026
Same author

Bacterial Lysates Add-On Therapy to Reduce Postoperative Recurrence in Nasal Polyps.

The Laryngoscope·2026
Same author

A single-cell atlas of the human airways from patients with allergic rhinitis comorbid with asthma.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2026
Same author

Effect of bacterial vaginosis on induced labour in the third trimester of pregnancy: a retrospective cohort study.

BMC pregnancy and childbirth·2026
Same author

The Application of Single-cell RNA Sequencing Technology in the Research of Sino-Nasal Diseases.

Clinical reviews in allergy & immunology·2026

Related Experiment Video

Updated: May 15, 2026

Body Composition and Metabolic Caging Analysis in High Fat Fed Mice
10:28

Body Composition and Metabolic Caging Analysis in High Fat Fed Mice

Published on: May 24, 2018

FewShotMetabolic: Parameter-Efficient Transfer Learning for Rapid Metabolic Risk Prediction in Data-Scarce Obesity

Shiqi Mo, Xiumei Wu, Huijun Qiu

    IEEE Journal of Biomedical and Health Informatics
    |May 13, 2026
    PubMed
    Summary

    The FewShotMetabolic (FSM) Framework enables accurate metabolic risk prediction for rare obesity types using minimal data. This approach facilitates precision obesity medicine for underrepresented populations.

    Related Experiment Videos

    Last Updated: May 15, 2026

    Body Composition and Metabolic Caging Analysis in High Fat Fed Mice
    10:28

    Body Composition and Metabolic Caging Analysis in High Fat Fed Mice

    Published on: May 24, 2018

    Area of Science:

    • Metabolic disease research
    • Precision medicine
    • Computational biology

    Background:

    • Developing metabolic risk prediction models for obesity is hindered by the need for large datasets, especially for rare obesity phenotypes.
    • Current technologies struggle to account for inter-phenotype variability, limiting clinical research translation for underrepresented groups.

    Purpose of the Study:

    • To introduce the FewShotMetabolic (FSM) Framework, a parameter-efficient approach for creating individualized metabolic risk models.
    • To enable accurate risk prediction using limited data (10 points) for diverse obesity phenotypes.
    • To facilitate knowledge sharing between obesity phenotypes while preserving unique metabolic signatures.

    Main Methods:

    • Developed the FewShotMetabolic (FSM) Framework, a parameter-efficient model.
    • Utilized selective pathway fine-tuning to maintain distinct metabolic signatures for each obesity phenotype.
    • Enabled knowledge transfer across different obesity phenotypes.

    Main Results:

    • Achieved 87.3% accuracy (AUC = 0.923) in classifying metabolic syndrome risk across six obesity subtypes.
    • Demonstrated a significant reduction in learnable parameters (17.2% of fine-tuned models).
    • Estimated 2-hour post-meal glycemic response with an RMSE of 14.2 mg/dL (Pearson r = 0.876).
    • Validated performance in external cohorts with AUC > 0.89.

    Conclusions:

    • The FSM Framework provides a practical solution for precision obesity medicine.
    • Enables the development of predictive models for historically underrepresented populations.
    • Advances the application of machine learning in metabolic disease research.